TIGAR通过调控ROS水平影响黑色素瘤的增殖
Regulation of Melanoma Proliferation by TIGAR via ROS Level Modulation
DOI: 10.12677/acm.2026.1641604, PDF,   
作者: 李 玮, 刘育彤, 陈云泽, 蔡 霞*：青岛大学附属医院整形外科，山东 青岛；高学军：青岛大学附属医院甲状腺外科，山东 青岛
关键词: 黑色素瘤；TIGAR；活性氧；Melanoma； TIGAR； ROS
摘要: 黑色素瘤是起源于黑色素细胞的高度恶性肿瘤，具有高侵袭性与高致死率，全球发病率持续攀升，已成为严重威胁人类健康的恶性肿瘤之一。本研究通过生物信息学分析筛选获得关键基因TIGAR，并基于TCGA数据库证实其在黑色素瘤中高表达且与不良预后显著相关。在此基础上，采用SiRNA介导的基因敲低实验，进一步探究TIGAR对细胞内ROS水平的调控作用，并阐明其通过ROS依赖途径影响黑色素瘤细胞增殖的分子机制，为黑色素瘤的发病机制研究提供新的线索与实验依据。结果显示，TIGAR高表达与患者不良预后显著相关。敲低TIGAR可上调细胞内ROS水平，抑制黑色素瘤细胞增殖。研究证实，TIGAR在黑色素瘤增殖中起关键调控作用，为阐明其病理生理机制及开发潜在治疗靶点提供理论依据。
Abstract: Melanoma is a highly malignant tumor originating from melanocytes, characterized by high invasiveness and high mortality. Its global incidence continues to rise, making it one of the malignant tumors that pose a severe threat to human health. In this study, the key gene TIGAR was identified through bioinformatics analysis, and its high expression in melanoma and significant correlation with poor prognosis were verified based on the TCGA database. Furthermore, gene knockdown mediated by SiRNA was performed to investigate the regulatory effect of TIGAR on intracellular ROS levels, and to clarify the molecular mechanism by which it modulates the proliferation of melanoma cells through a pathway dependent on ROS. These findings provide novel insights and experimental evidence for exploring the pathogenesis of melanoma. The results demonstrated that high TIGAR expression was significantly associated with poor prognosis in patients. Knockdown of TIGAR increased intracellular ROS levels and inhibited the proliferation of melanoma cells. Collectively, this study confirms that TIGAR functions as a key regulator in melanoma proliferation, providing a theoretical basis for elucidating its pathophysiological mechanism and developing potential therapeutic targets.
文章引用：李玮, 高学军, 刘育彤, 陈云泽, 蔡霞. TIGAR通过调控ROS水平影响黑色素瘤的增殖[J]. 临床医学进展, 2026, 16(4): 3413-3424. https://doi.org/10.12677/acm.2026.1641604

参考文献

[1] 李卓林, 贾如雪, 吴亚婷, 张胜行, 王水良. 肿瘤转移的分子机制及靶向干预研究新进展[J]. 中华细胞与干细胞杂志, 2022, 12(1): 51-58.
[2] Wang, J.Y., Wang, E.B. and Swetter, S.M. (2023) What Is Melanoma? JAMA, 329, Article 948. [Google Scholar] [CrossRef] [PubMed]
[3] He, X., Deng, H., Liu, W., Hu, L. and Tan, X. (2024) Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma. Current Treatment Options in Oncology, 25, 1615-1633. [Google Scholar] [CrossRef] [PubMed]
[4] Zhou, X., An, B., Lin, Y., Ni, Y., Zhao, X. and Liang, X. (2023) Molecular Mechanisms of Ros-Modulated Cancer Chemoresistance and Therapeutic Strategies. Biomedicine & Pharmacotherapy, 165, Article 115036. [Google Scholar] [CrossRef] [PubMed]
[5] Fendt, S. and Lunt, S.Y. (2020) Dynamic ROS Regulation by TIGAR: Balancing Anti-Cancer and Pro-Metastasis Effects. Cancer Cell, 37, 141-142. [Google Scholar] [CrossRef] [PubMed]
[6] Halliwell, B. (2012) Free Radicals and Antioxidants: Updating a Personal View. Nutrition Reviews, 70, 257-265. [Google Scholar] [CrossRef] [PubMed]
[7] Schieber, M. and Chandel, N.S. (2014) ROS Function in Redox Signaling and Oxidative Stress. Current Biology, 24, R453-R462. [Google Scholar] [CrossRef] [PubMed]
[8] Murphy, M.P. (2014) Antioxidants as Therapies: Can We Improve on Nature? Free Radical Biology and Medicine, 66, 20-23. [Google Scholar] [CrossRef] [PubMed]
[9] Elia, I., Doglioni, G. and Fendt, S. (2018) Metabolic Hallmarks of Metastasis Formation. Trends in Cell Biology, 28, 673-684. [Google Scholar] [CrossRef] [PubMed]
[10] Teoh, S.T. and Lunt, S.Y. (2018) Metabolism in Cancer Metastasis: Bioenergetics, Biosynthesis, and Beyond. WIREs Systems Biology and Medicine, 10, e1406. [Google Scholar] [CrossRef] [PubMed]
[11] Prasad, S., Gupta, S.C. and Tyagi, A.K. (2017) Reactive Oxygen Species (ROS) and Cancer: Role of Antioxidative Nutraceuticals. Cancer Letters, 387, 95-105. [Google Scholar] [CrossRef] [PubMed]
[12] Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T.D., Mazur, M. and Telser, J. (2007) Free Radicals and Antioxidants in Normal Physiological Functions and Human Disease. The International Journal of Biochemistry & Cell Biology, 39, 44-84. [Google Scholar] [CrossRef] [PubMed]
[13] Bensaad, K., Tsuruta, A., Selak, M.A., Vidal, M.N.C., Nakano, K., Bartrons, R., et al. (2006) TIGAR, a P53-Inducible Regulator of Glycolysis and Apoptosis. Cell, 126, 107-120. [Google Scholar] [CrossRef] [PubMed]
[14] Green, D.R. and Chipuk, J.E. (2006) P53 and Metabolism: Inside the Tigar. Cell, 126, 30-32. [Google Scholar] [CrossRef] [PubMed]
[15] Cheung, E.C., DeNicola, G.M., Nixon, C., Blyth, K., Labuschagne, C.F., Tuveson, D.A., et al. (2020) Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer. Cancer Cell, 37, 168-182.e4. [Google Scholar] [CrossRef] [PubMed]
[16] Cheung, E.C., Strathdee, D., Stevenson, D., Coomes, J., Blyth, K. and Vousden, K.H. (2024) Regulation of ROS Signaling by TIGAR Induces Cancer-Modulating Responses in the Tumor Microenvironment. Proceedings of the National Academy of Sciences, 121, e2416076121. [Google Scholar] [CrossRef] [PubMed]
[17] Brandl, N., Seitz, R., Sendtner, N., Müller, M. and Gülow, K. (2025) Living on the Edge: ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target. Antioxidants, 14, Article 1002. [Google Scholar] [CrossRef] 
[18] Hong, M., Xia, Y., Zhu, Y., Zhao, H., Zhu, H., Xie, Y., et al. (2016) Tp53-Induced Glycolysis and Apoptosis Regulator Protects from Spontaneous Apoptosis and Predicts Poor Prognosis in Chronic Lymphocytic Leukemia. Leukemia Research, 50, 72-77. [Google Scholar] [CrossRef] [PubMed]
[19] Won, K.Y., Lim, S., Kim, G.Y., Kim, Y.W., Han, S., Song, J.Y., et al. (2012) Regulatory Role of P53 in Cancer Metabolism via SCO2 and TIGAR in Human Breast Cancer. Human Pathology, 43, 221-228. [Google Scholar] [CrossRef] [PubMed]
[20] Al-Khayal, K., Abdulla, M., Al-Obeed, O., Kattan, W.A., Zubaidi, A., Vaali-Mohammed, M., et al. (2016) Identification of the Tp53-Induced Glycolysis and Apoptosis Regulator in Various Stages of Colorectal Cancer Patients. Oncology Reports, 35, 1281-1286. [Google Scholar] [CrossRef] [PubMed]
[21] Zhao, M., Fan, J., Liu, Y., Yu, Y., Xu, J., Wen, Q., et al. (2015) Oncogenic Role of the Tp53-Induced Glycolysis and Apoptosis Regulator in Nasopharyngeal Carcinoma through NF-κB Pathway Modulation. International Journal of Oncology, 48, 756-764. [Google Scholar] [CrossRef] [PubMed]
[22] Liu, J., Lu, F., Gong, Y., Zhao, C., Pan, Q., Ballantyne, S., et al. (2018) High Expression of Synthesis of Cytochrome C Oxidase 2 and Tp53-Induced Glycolysis and Apoptosis Regulator Can Predict Poor Prognosis in Human Lung Adenocarcinoma. Human Pathology, 77, 54-62. [Google Scholar] [CrossRef] [PubMed]
[23] Feng, Y., Meng, Y., Zhang, M., Ying, Y., Yao, Y. and Li, D. (2025) TIGAR Inhibits Glucose-Metabolism and Cisplatin-Chemosensitivity in Human Lung Cancer Cells. Discover Oncology, 16, Article 1420. [Google Scholar] [CrossRef] [PubMed]
[24] Peña-Rico, M.A., Calvo-Vidal, M.N., Villalonga-Planells, R., Martínez-Soler, F., Giménez-Bonafé, P., Navarro-Sabaté, À., et al. (2011) TP53 Induced Glycolysis and Apoptosis Regulator (TIGAR) Knockdown Results in Radiosensitization of Glioma Cells. Radiotherapy and Oncology, 101, 132-139. [Google Scholar] [CrossRef] [PubMed]
[25] Maddocks, O.D.K., Athineos, D., Cheung, E.C., Lee, P., Zhang, T., van den Broek, N.J.F., et al. (2017) Modulating the Therapeutic Response of Tumours to Dietary Serine and Glycine Starvation. Nature, 544, 372-376. [Google Scholar] [CrossRef] [PubMed]
[26] Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., et al. (2015) Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. Nucleic Acids Research, 43, e47-e47. [Google Scholar] [CrossRef] [PubMed]
[27] Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., et al. (2000) Gene Ontology: Tool for the Unification of Biology. Nature Genetics, 25, 25-29. [Google Scholar] [CrossRef] [PubMed]
[28] Rojas, K.D., Perez, M.E., Marchetti, M.A., Nichols, A.J., Penedo, F.J. and Jaimes, N. (2022) Skin Cancer: Primary, Secondary, and Tertiary Prevention. Part II. Journal of the American Academy of Dermatology, 87, 271-288. [Google Scholar] [CrossRef] [PubMed]
[29] Perez, M., Abisaad, J.A., Rojas, K.D., Marchetti, M.A. and Jaimes, N. (2022) Skin Cancer: Primary, Secondary, and Tertiary Prevention. Part I. Journal of the American Academy of Dermatology, 87, 255-268. [Google Scholar] [CrossRef] [PubMed]
[30] Arnold, M., Singh, D., Laversanne, M., Vignat, J., Vaccarella, S., Meheus, F., et al. (2022) Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatology, 158, 495-503. [Google Scholar] [CrossRef] [PubMed]
[31] Sample, A. and He, Y. (2018) Mechanisms and Prevention of UV‐Induced Melanoma. Photodermatology, Photoimmunology & Photomedicine, 34, 13-24. [Google Scholar] [CrossRef] [PubMed]
[32] Gilchrest, B.A., Eller, M.S., Geller, A.C. and Yaar, M. (1999) The Pathogenesis of Melanoma Induced by Ultraviolet Radiation. New England Journal of Medicine, 340, 1341-1348. [Google Scholar] [CrossRef] [PubMed]
[33] Naimy, S., Sølberg, J.B.K., Kuczek, D.E., Løvendorf, M.B., Bzorek, M., Litman, T., et al. (2024) Comparative Quantitative Proteomic Analysis of Melanoma Subtypes, Nevus-Associated Melanoma, and Corresponding Nevi. Journal of Investigative Dermatology, 144, 1608-1621.e4. [Google Scholar] [CrossRef] [PubMed]
[34] Bertolotto, C. (2024) Mechanisms of Melanoma Aggressiveness with Age. Nature Aging, 4, 287-288. [Google Scholar] [CrossRef] [PubMed]
[35] Li, A., Gong, Z., Long, Y., Li, Y., Liu, C., Lu, X., et al. (2025) Lactylation of LSD1 Is an Acquired Epigenetic Vulnerability of BRAFi/Meki-Resistant Melanoma. Developmental Cell, 60, 1974-1990.e11. [Google Scholar] [CrossRef] [PubMed]
[36] Qian, S., Li, J., Hong, M., Zhu, Y., Zhao, H., Xie, Y., et al. (2016) TIGAR Cooperated with Glycolysis to Inhibit the Apoptosis of Leukemia Cells and Associated with Poor Prognosis in Patients with Cytogenetically Normal Acute Myeloid Leukemia. Journal of Hematology & Oncology, 9, Article No. 128. [Google Scholar] [CrossRef] [PubMed]
[37] Cheung, E.C., Athineos, D., Lee, P., Ridgway, R.A., Lambie, W., Nixon, C., et al. (2013) TIGAR Is Required for Efficient Intestinal Regeneration and Tumorigenesis. Developmental Cell, 25, 463-477. [Google Scholar] [CrossRef] [PubMed]
[38] Ko, Y., Domingo-Vidal, M., Roche, M., Lin, Z., Whitaker-Menezes, D., Seifert, E., et al. (2016) Tp53-Inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer. Journal of Biological Chemistry, 291, 26291-26303. [Google Scholar] [CrossRef] [PubMed]
[39] Liu, Z., Wu, Y., Zhang, Y., Yuan, M., Li, X., Gao, J., et al. (2019) TIGAR Promotes Tumorigenesis and Protects Tumor Cells from Oxidative and Metabolic Stresses in Gastric Cancer. Frontiers in Oncology, 9, Article ID: 1258. [Google Scholar] [CrossRef] [PubMed]
[40] Huang, S., Yang, Z., Ma, Y., Yang, Y. and Wang, S. (2017) Mir-101 Enhances Cisplatin-Induced DNA Damage through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells. DNA and Cell Biology, 36, 303-310. [Google Scholar] [CrossRef] [PubMed]
[41] Mu, Y., Wang, Q., Tan, L., Lin, L. and Zhang, B. (2020) Microrna-144 Inhibits Cell Proliferation and Invasion by Directly Targeting TIGAR in Esophageal Carcinoma. Oncology Letters, 19, 3079-3088. [Google Scholar] [CrossRef] [PubMed]
[42] Wei, M., Peng, J., Wu, P., Chen, P., Yang, H., Cui, Y., et al. (2018) Prognostic Value of TIGAR and LC3B Protein Expression in Nasopharyngeal Carcinoma. Cancer Management and Research, 10, 5605-5616. [Google Scholar] [CrossRef] [PubMed]
[43] Tang, J., Chen, L., Qin, Z. and Sheng, R. (2021) Structure, Regulation, and Biological Functions of TIGAR and Its Role in Diseases. Acta Pharmacologica Sinica, 42, 1547-1555. [Google Scholar] [CrossRef] [PubMed]
[44] Yu, H., Xie, J., Li, B., Sun, Y., Gao, Q., Ding, Z., et al. (2015) TIGAR Regulates DNA Damage and Repair through Pentosephosphate Pathway and Cdk5-ATM Pathway. Scientific Reports, 5, Article No. 9853. [Google Scholar] [CrossRef] [PubMed]
[45] Yapindi, L., Hernandez, B.Y. and Harrod, R. (2021) siRNA-Inhibition of TIGAR Hypersensitizes Human Papilloma-virus-Transformed Cells to Apoptosis Induced by Chemotherapy Drugs that Cause Oxidative Stress. Journal of Antivirals & Antiretrovirals, 13, Article No. 223.

为你推荐